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Background. A CrT substitution at position 589 in the interleukin-4 (IL-4) gene is associated with increased
production of IL-4. Associations between this polymorphism and recurrent vulvovaginal candidiasis (RVVC), as
well as vaginal concentrations of IL-4 and the anticandidal compounds nitric oxide (NO) and mannose binding
lectin (MBL), were evaluated.
Methods. Vaginal samples obtained by lavage from 42 women with RVVC during the acute stage of the disease
and 43 control samples were assayed by enzyme-linked immunosorbent assay for IL-4 and NO metabolites. The
589 IL-4 gene polymorphism was detected by polymerase chain reaction and endonuclease digestion. Data were
analyzed by Fisher’s exact test, the nonparametric Mann-Whitney and Kruskal-Wallis tests, and Spearman rank
correlation. was considered significant.P ! .05
Results. Candida albicans was identified in 38 patients with RVVC; 3 others had infection due to Candida
tropicalis, and 1 had infection due to Candida krusei. The IL-4 T,T genotype was detected in 59.5% of patients
with RVVC and in 7.0% of control subjects ( ). The frequency of IL-4*T was 76.2% in patients withP ! .0001
RVVC and 23.3% in control subjects ( ). The median concentration of vaginal IL-4 was elevated in patientsP ! .0001
with RVVC, compared with control subjects ( ). Conversely, vaginal concentrations of NO metabolitesP ! .0001
( ) and MBL ( ) were reduced in patients with RVVC. There was a positive association betweenP p .02 P ! .0001
IL-4*T homozygosity and vaginal IL-4 levels ( ) and negative associations between this genotype andP ! .0001
vaginal NO ( ) and MBL ( ) concentrations.P p .01 P ! .0001
Conclusions. Reduced vaginal levels of anticandidal factors in IL-4*T homozygotes may increase susceptibility
to RVVC.
Candida albicans is a dimorphic yeast that inhabits the
vagina as a nonpathogenic commensal microorganism
in up to 30% of women of reproductive age [1, 2].
Colonization with C. albicans can occur during passage
of the newborn infant through the birth canal [3].
Therefore, the vast majority of colonized women have
readily detectable anti-Candida humoral and cell-me-
diated immunity [4, 5]. In contrast, laboratory animals
used in candidal vaginitis–directed research are not nor-
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mally colonized with C. albicans [6]. Therefore, local
and systemic anticandidal immune defense mechanisms
might be quite different in animals and in humans [2].
In addition, polymorphonuclear leukocytes are the pri-
mary vaginal anticandidal immune defense mechanism
in experimental animals, but these cells are typically
absent from women with vaginal candidal infections
[7]. The mechanisms involved in the conversion of C.
albicans from a commensal to a vaginal pathogen re-
main incompletely understood.
There has been a lack of agreement on identification
of a specific acquired cell-mediated or humoral im-
mune mechanism responsible for development of a
symptomatic candidal vaginal infection in colonized
women. Because of the large number of factors and
pathways that can contribute to the development of a







llibrary user on 07 O
ctober 2021
IL-4 Gene Polymorphism and Candidiasis • CID 2005:40 (1 May) • 1259
of consistent findings among different investigators is not too
surprising. The conflicting data obtained to date have been
recently reviewed [8].
A more recent approach to the problem of why certain in-
fections or other disorders occur repeatedly in some women
but not in others has been to evaluate possible genetic differ-
ences between patients and control subjects. The association
between a polymorphism in the gene coding for complement
component C3 and enhanced inflammatory responses to Can-
dida infections has been reported [9]. A genetic polymorphism
in the gene coding for mannose-binding lectin (MBL) that
results in decreased MBL levels recently has been shown to
occur with increased frequency in women with recurrent vul-
vovaginal candidiasis (RVVC) [10]. MBL, a component of the
innate immune system, binds to mannan residues on C. albicans
and promotes complement activation and killing [11]. Nitric
oxide (NO) is another major component of the innate immune
defense against microorganisms [12]. The anti-Candida activity
of macrophage-derived NO is strongly inhibited by IL-4 [13].
IL-4 is a cytokine product of the Th2 subset of T lymphocytes.
It inhibits production of proinflammatory cytokines by Th1 T
cells and blocks macrophage activation [14]. A single nucleotide
polymorphism consisting of a CrT transition at position 589
in the promoter region of the IL-4 gene has been identified.
Possession of the T variant is associated with increased IL-4
production [15].
We hypothesized that the variant IL-4 589 T allele (IL4*T)
is a gene polymorphism associated with RVVC because of in-
creased concentrations of vaginal IL-4 and decreased NO and
MBL concentrations.
METHODS
The study group consisted of 42 women aged 18–35 years,
examined at Riga First Hospital in Latvia between 2001 and
2002, who had genital itching and/or abnormal vaginal dis-
charge and positive results of culture for Candida and a history
of at least 4 clinical episodes of culture-positive vulvovaginal
candidiasis in the preceding 12 months. The control group
consisted of 43 age-matched healthy women without any vag-
inal complaints and with no history of a vaginal yeast infection.
Details of sample collection, demographic information, and the
diagnosis of vaginal Candida species, bacterial vaginosis, and
other vaginal microorganisms in this study population have
been reported previously [10]. Briefly, cervicovaginal samples
were obtained by instilling 3 mL of sterile saline into the pos-
terior vagina, mixing the saline with secretions, and withdraw-
ing the solution with a syringe. All vaginal lavage samples were
centrifuged to separate supernatant and pellet fractions and
immediately frozen at 20C; afterwards, each fraction was
shipped on dry ice to Weill Medical College of Cornell Uni-
versity in New York for analysis.
Vaginal NO production was determined by measuring total
vaginal nitrite and nitrate concentrations of undiluted samples
with a commercial ELISA (StressXpress). The lower limit of
sensitivity was 1.35 mmol/L. IL-4 levels were determined by
commercial ELISA (BioSource). The lower limit of sensitivity
was 0.9 pg/mL. Vaginal MBL concentrations for both patients
and control subjects were previously reported [10].
For the IL-4 genetic polymorphism analysis, sample pellets
were thawed, washed, and resuspended in a 1% solution of the
nonionic detergent Brij 35 in Tris-HCl buffer, pH 7.5, con-
taining 5 mg/mL proteinase K. Cells were lysed by incubation
at 56C for 60 min, and the proteinase K was then inactivated
by increasing the temperature to 95C for 10 min. The lysed
samples were diluted 1:5 in 10 mmol/L Tris-HCl that contained
1.5 mmol/L MgCl2; 50 mmol/L KCl; 0.2 mmol/L each of de-
oxyadenosine triphosphate, deoxycitidine triphosphate, deox-
yguanosine triphosphate, and thymidine triphosphate; 1.25 U
of Taq DNA polymerase; and 30 pmol of oligonucleotide prim-
ers that amplified the polymorphic region at position 589 in
the IL-4 promoter [16]. The final volume was 0.05 mL. Am-
plification conditions were 35 cycles of 95C for 30 s, 57C for
30 s, and 72C for 30 s. The PCR product was digested by
incubation at 65C for 18 h with BsmFI restriction enzyme
(New England BioLabs) in buffer provided by the manufac-
turer. The wild type allele generated a product that was cut into
192- and 60-bp fragments, whereas the mutant product re-
mained uncut at 252 bp. The products of the PCR reaction
were resolved by electrophoresis on a 3% agarose gel stained
with ethidium bromide.
Genotype and allele frequencies were determined by direct
counting and then dividing by the number of chromosomes
to obtain allele frequency and by the number of women to
obtain genotype frequency. Differences in genotype and allele
frequencies between patients and control subjects were analyzed
with use of Fisher’s exact test. Hardy-Weinberg equilibrium
was determined with use of a x2 goodness-of-fit test on the
basis of expected frequencies. The expected frequencies were
calculated with use of the assumption of Hardy-Weinberg equi-
librium. Differences in median vaginal concentrations of IL-4,
NO, and MBL between patients and controls were analyzed
with the nonparametric Mann-Whitney test. The association
between IL-4 genotype and vaginal concentrations of IL-4, NO,
and MBL were determined by the Kruskal-Wallis test. Corre-
lations between the concentrations of any 2 vaginal compounds
were analyzed by Spearman rank correlation. P !.05 was con-
sidered statistically significant.
RESULTS
The distribution of the IL-4 genotypes at position 589 differed
between patients with RVVC and controls (table 1). Homo-
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Table 1. Frequency of IL-4 gene polymorphisms in women with




P RR (95% CI)Control RVVC
Genotype
C,C 26/43 (60.5) 3/42 (7.1) !.0001 0.149 (0.559–0.812)
C,T 14/43 (32.6) 14/42 (33.3)
T,T 3/43 (7.0) 25/42 (59.5) !.0001 2.994 (1.970–4.549)
Allele
C 66/86 (76.7) 20/84 (23.8)
T 20/86 (23.3) 64/84 (76.2) !.0001 3.276 (2.191–4.898)
Table 2. Association of IL-4 genotype with clinical and demographic data








Age, mean years (range) 23.0 (18–29) 27.8 (19–35) 26.7 (18–35)
Pregnancies, mean no. (range) 2.3 (0–5) 1.8 (0–4) 2.8 (0–8)
Births, mean no. (range) 0.3 (0–4) 1.1 (0–3) 1.2 (0–3)
Married 1 (33.3) 8 (57.1) 11 (44.0)
Smoker 3 (100)a 3 (21.4) 6 (24.0)
College education 0 8 (57.1) 13 (52.0)
Gram-positive bacteria 0 2 (14.3) 6 (24.0)
Gram-negative bacteria 0 4 (28.6) 2 (8.0)
Presence of Urea urealyticum 1 (33.3) 2 (14.3) 6 (24.0)
Bacterial vaginosis 2 (66.7) 4 (28.6) 4 (16.0)
NOTE. Unless indicated otherwise, data are no. (%) of patients with the specified
parameter.
a vs. C,T and T,T.P p .02
with RVVC, compared with 7.0% of control subjects (P !
). Conversely, homozygosity for IL4*C was present in.0001
60.5% of control subjects and 7.1% of patients with RVVC
( ). The frequency of the IL4*T allele was 76.2% inP ! .0001
patients with RVVC and only 23.3% in control subjects (P !
). The frequencies of IL-4 genotypes in both patients.0001
with RVVC and control subjects were in Hardy-Weinberg
equilibrium.
Four patients with RVVC had results positive for Candida
species other than C. albicans: 3 had results positive for Candida
tropicalis, and 1 had results positive for Candida krusei. Two
of the women with C. tropicalis infection and the woman with
C. krusei infection were IL4*T homozygotes; the other patient
who was infected with C. tropicalis- was a IL4*T/IL4*C het-
erozygote. Demographic and clinical characteristics of the pa-
tients with RVVC in relation to their IL-4 genotype are shown
in table 2. The only significant difference noted was a higher
percentage of smokers among IL4*C homozygotes than among
the other 2 groups ( ). Four of the control subjectsP p .02
also had cultures positive for C. albicans. All were IL4*C
homozygous.
Vaginal concentrations of IL-4 and NO in both patient and
control groups are shown in table 3. Median IL-4 levels were
higher ( ) and median NO levels were lower (P ! .0001 P p
) in patients with RVVC than in controls. There were no.02
differences in vaginal IL-4 and NO levels in the RVVC group
between those with results positive or negative for Candida
species other than C. albicans or between those with results
positive or negative for bacterial vaginosis (data not shown).
The relationship between IL-4 genotype and vaginal con-
centrations of IL-4 and NO is shown in table 4. Homozygosity
for the variant IL4*T allele was associated with elevated vaginal
concentrations of IL-4 ( ). Conversely, possession ofP ! .0001
this genotype was associated with reduced vaginal concentra-
tions of NO ( ).P p .01
There was an inverse correlation between vaginal concen-
trations of IL-4 and NO (Spearman ; ).r p .257 P p .02
DISCUSSION
Results of the present study, as well as results of our previous
investigation, highlight a genetic influence on susceptibility to
RVVC. Possession of variant alleles associated with reduced
vaginal concentrations of MBL [10] or increased vaginal IL-4
levels occur at a higher rate in women with RVVC than in a
control population. The number of subjects in our study group
was insufficient to analyze whether simultaneous carriage of
both gene polymorphisms was associated with a further increase
in the rate of RVVC. Nevertheless, the data from the 2 inves-
tigations strongly support the hypothesis that a woman’s ge-
netic capacity to produce IL-4 and MBL influences her likeli-
hood of developing RVVC.
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Table 3. Vaginal concentrations of IL-4 and nitric oxide me-











IL-4, pg/mL !0.9 (!0.9–1.5) 2.5 (!0.9–11.2) !.0001
Nitric oxide, mmol/L 10.2 (!1.3–42.5) 4.0 (!1.3–66.1) .02
Table 4. Association between IL-4 gene poly-
morphism and vaginal concentrations of IL-4 and
nitric oxide (NO) metabolites.
IL-4 genotype
Median concentration (range)
IL-4, pg/mL NO, mmol/L
C,C 0.9 (!0.9–5.7)a 12.4 (!1.3–57.3)b
C,T 1.2 (!0.9–11.2) 4.3 (!1.3–42.5)
T,T 2.2 (!0.9–9.1) 3.9 (!1.3–66.1)
a .P ! .0001
b .P p .01
at least in part, by the inhibition of NO production [13]. In
the present study, homozygous carriage of IL4*T was associated
with both a 12-fold increase in the vaginal concentration of
IL-4 and a 3-fold decrease in vaginal NO production. MBL
vaginal levels in the study population were reported previously
[10], and IL4*T homozygosity was also associated with a 12-
fold decrease in the median vaginal MBL concentration (7.3
ng/mL vs. 15.5 ng/mL for IL4*C homozygotes). Similarly, there
was a strong inverse relationship between vaginal concentra-
tions of IL-4 and MBL (Spearman ; ). MBLr p .728 P ! .0001
is an acute-phase reactant, and it is possible that a macrophage-
activation product induces vaginal MBL production. The cells
in the female genital tract that produce MBL have yet to be
identified. It appears that a woman’s IL-4 genotype at position
589 influences the vaginal concentrations of 2 major com-
ponents of the innate immune response against infection. The
data, therefore, also highlight a central role for innate immune
mechanisms in protection against development of symptomatic
Candida vaginitis.
The results of our genetic studies offer new insights into the
factors that influence conversion of Candida from a commensal
microorganism to a vaginal pathogen. The elaboration of a
proinflammatory anti-Candida cytokine response by healthy
women results in the recruitment and activation of macro-
phages that eliminate or reduce the vaginal Candida concen-
tration. The presence of MBL receptors on macrophages allows
these cells to bind and ingest Candida that have become as-
sociated with MBL present in the vagina. The release of NO
by activated macrophages results in the production of toxic
radicals that kill Candida. Activated macrophages release proin-
flammatory cytokines that stimulate Th1 lymphocytes to fur-
ther inhibit proliferation of Candida. Th1 cells release IFN-g,
which blocks the capacity of C. albicans yeast cells to initiate
germ tube formation and convert from the yeast to the more
invasive fungal form [17]. Macrophage and T cell activation also
fosters the prolongation of antimicrobial responses. An enhance-
ment of production of anti-inflammatory cytokines in the vagina,
possibly due to a genetic propensity to produce IL-4 and/or other
anti-inflammatory mediators or to decreased levels of MBL, in-
duction of a vaginal allergic response accompanied by histamine
release [18, 19] and production of prostaglandin E2 [19, 20] or
the concomitant presence of microbial or nonmicrobial Th2 in-
ducers diminishes the ability to limit proliferation of Candida.
If Candida is present as a commensal microorganism, these con-
ditions would allow the replication and germination of the yeast
and lead to a symptomatic infection.
It can be seen that RVVC is the end result of several dif-
ferent pathways. Treatment of a woman’s current Candida
infection will alleviate her symptoms, but this will do little
to decrease her susceptibility to developing another symp-
tomatic infection. Because local and systemic azoles are static
(not cidal) drugs, these patients are dependent on local host
defense mechanisms to eliminate a vaginal candidal infection.
Identification of the specific underlying systems in individual
women with RVVC that are responsible for a decreased ef-
ficiency in killing of Candida and initiating specific measures
to counteract the observed deficiency will lead to more-ef-
fective and longer-lasting treatments.
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